Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

ting of three large clinical trials that are expected to enroll approximately 1,000 patients with genotype-1 HCV at clinical centers in the United States, Canada and Europe. In these clinical trials, telaprevir is being dosed as 750 mg every eight hours in combination with pegylated interferon alfa-2a (Pegasys(R)), both with and without ribavirin (Copegus(R)).

Vertex retains commercial rights to telaprevir in North America. Vertex and Tibotec are collaborating to develop and commercialize telaprevir in Europe, South America, Australia, the Middle East, and other countries. Vertex is collaborating with Mitsubishi Pharma to develop and commercialize telaprevir in Japan and certain Far East countries.

About Hepatitis C

Hepatitis C is a liver disease caused by infection with hepatitis C virus (HCV), which is found in the blood of people with the disease. HCV, a serious public health concern affecting 170 million people worldwide, is spread through direct contact with the blood of an infected person. Though many people with hepatitis C may not experience symptoms, others may have symptoms such as jaundice, abdominal pain, fatigue and fever. Hepatitis C significantly increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and early death.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Vertex's press releases are available at www.vrtx.com.

About Tibotec

Tibotec Pharmaceuticals, Ltd., based in Cork, Ireland, is a pharm
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:4/24/2015)...  Elekta has CE marked the latest version (v5.10) ... enabling European clinics to deliver a sophisticated radiation therapy ... 3D planning, IMRT, VMAT and stereotactic planning – all ... Monaco ® v5.10 provides significant planning ... in 3D planning as well as the addition of ...
(Date:4/23/2015)... April 23, 2015  ResMed Inc. (NYSE: RMD ... 31, 2015.  Revenue for the quarter was $422.5 million, ... March 31, 2014 (a 13 percent increase on a ... increase of 1 percent compared to the quarter ended ... quarter were $0.64, an increase of 2 percent compared ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... 5, 2011 Express Scripts contributed more than $226 ... economic analysis of the company,s data by a university ... The economic impact study, presented today to state economic ... support 2,665 direct and indirect jobs in the state. ...
... NeuroVasx announced today that the FDA ... Humanitarian Use Device (HDE) for the treatment of large, ... most difficult to treat.  The HDE allows for the ... the U.S. (Logo: http://photos.prnewswire.com/prnh/20110405/CG77724LOGO ) ...
Cached Medicine Technology:Express Scripts Injects $226 Million Into Arizona Economy, Study Finds 2NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System 2
(Date:4/26/2015)... Indiana (PRWEB) April 26, 2015 Indiana ... service provider announces that Brotherhood Mutual Insurance Company has ... Armstrong, Manager of Network Infrastructure at Brotherhood Mutual Insurance ... and the service reliability Brotherhood Mutual needed. ... diversity, and IFN worked with us to ensure we ...
(Date:4/26/2015)... FL (PRWEB) April 26, 2015 A ... pieces of medical equipment from hospitals, surgery centers and ... of equipment will be sold including radiology, surgery, endoscopy, ... live auction will take place Tuesday, April 28th starting ... Lauderdale warehouse located at 5025 North Hiatus Rd., Sunrise, ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... MidSouth Pain Treatment Center has announced ... Treatment Center is a comprehensive pain management center including ... two ambulatory surgery centers in Germantown and Southaven, and ... , Dr. Michael Steuer , founder of MidSouth ... people, and when I discovered that I could make ...
(Date:4/25/2015)... California (PRWEB) April 26, 2015 Avid ... search for original 1965 Rolling Stones Greensboro Coliseum concert posters. ... was part of the Stone's Second American Tour. ... Globe Poster Company out of Baltimore, Maryland. This poster ... the northeast and southern cites. Globe uses garish lettering ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2
... Enjoying the eating process without focus on dietary restrictions ... according to researchers who have unveiled a new and ... Competence Model, also known as ecSatter, was created by ... of Secrets of Feeding a Healthy Family, Kelcy ...
... Significant Data Detailed at a Late-Breaking Presentation at ... ... 18 Iomai,Corporation (Nasdaq: IOMI ) today announced that travelers ... be sickened as compared with travelers who receive a placebo,according to ...
... (NYSE: AGP ) today announced that it ... and Medicare Services (CMS) to offer both,Medicare Advantage ... plans to address the specialized needs of seniors ... currently coordinates care for approximately 5,000,individuals through Medicare ...
... N.C., Sept. 18 Contact centers have been,transformed ... movement,that has reps selling while conducting ongoing customer ... skills are critical for,converting service reps to sales ... Practices, LLC. Ninety-eight percent of the 57 ...
... Researchers at the University of Pennsylvania School of ... Quality (AHRQ) have developed a framework to help ... challenges of implementing health information technology (HIT) by ... and quality. , As documented in a ...
... WASHINGTON, Sept. 18, 2007 -- A long-term study found ... patients with life-threatening diseases, such as leukemia and lymphoma, ... Further, males are likely to recover from these changes ... compromised. In addition, neither male nor female long-term cancer ...
Cached Medicine News:Health News:Nutrition model stresses positive experience of eating 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 3Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 4Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 5Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 2Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 3Health News:Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills 2Health News:Unanticipated consequences of health-care information technology 2Health News:Sexual function affected by stem cell transplant according to long-term study 2Health News:Sexual function affected by stem cell transplant according to long-term study 3Health News:Sexual function affected by stem cell transplant according to long-term study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: